Vol 12, No 6 (June 30, 2023) - Translational Lung Cancer Research

Makoto Nishio, Shinji Atagi, Koichi Goto, Yukio Hosomi, Takashi Seto, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshige Yoshioka, Naoyuki Nogami, Makoto Maemondo, Seisuke Nagase, Isamu Okamoto, Noboru Yamamoto, Yuriko Igawa, Kosei Tajima, Masahiro Fukuoka, Nobuyuki Yamamoto, Kazuto Nishio

PDF Pages: 1167-1184 Full Text (1374) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients

Sheehyun Kim, Sungjae Kim, Se Hyun Kim, Eun Hee Jung, Koung Jin Suh, Yu Jung Kim, Nak-Jung Kwon, Hyojin Kim, Jin-Haeng Chung, Jong Seok Lee

PDF Pages: 1185-1196 Full Text (796) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors

Jehun Kim, Tae Won Jang, Chang Min Choi, Mi Hyun Kim, Sung Yong Lee, Cheol Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon

PDF Pages: 1197-1209 Full Text (1296) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer

Krishna H. Patel, Naomi Alpert, Stephanie Tuminello, Emanuela Taioli

PDF Pages: 1210-1220 Full Text (529) Reporting Checklist Peer Review File COI Form Open Access

High NHLRC2 expression is associated with shortened survival in lung adenocarcinoma

Mervi A. Kreus, Siri T. Lehtonen, Johanna M. Mäkinen, H. Elisa Lappi-Blanco, Kirsi E. M. Laitakari, Shirley A. Johnson, Reetta M. L. Hinttala, Riitta L. Kaarteenaho

PDF Pages: 1221-1235 Full Text (879) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients

Ju-Yoon Yoon, Jacquelyn J. Roth, Chase A. Rushton, Jennifer J. D. Morrissette, Katherine L. Nathanson, Roger B. Cohen, Jason N. Rosenbaum

PDF Pages: 1236-1244 Full Text (715) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma

Kanako Nishimatsu, Yuji Matsumoto, Jumpei Kashima, Tatsuya Imabayashi, Keigo Uchimura, Hideaki Furuse, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Takaaki Tsuchida, Yuichiro Ohe, Yasushi Yatabe

PDF Pages: 1245-1255 Full Text (741) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated EGFR-mutant patients with advanced non-small cell lung cancer

Ting Li, Kejie Chang, Xin Qiu, Zhirong Lai, Yuanling Luo, Jiaqun Chen, Weize Lv, Zhong Lin, Xiaofeng Pei, Xiangwen Wu, Xiaojin Wang

PDF Pages: 1256-1263 Full Text (1134) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

A comparison of the microbiome composition in lower respiratory tract at different sites in early lung cancer patients

Kai Su, Yibo Gao, Jie He

PDF Pages: 1264-1275 Full Text (795) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer

Kaixuan Zhang, Hao Chen, Yan Jiang, Qiankun Chen, Bo Su, Xiao Zhou

PDF Pages: 1276-1292 Full Text (1173) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Five-year follow-up after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer: a multicenter study

Yanling Guo, Yaoyao Zhu, Ran Zhang, Shuangyan Yang, Lucyna Kepka, Gustavo Arruda Viani, Michael T. Milano, Terence T. Sio, Xiaojiang Sun, Hongyu Wu, Ligang Xing, Yaping Xu

PDF Pages: 1293-1302 Full Text (770) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Review Article

Patient-led advocacy in ALK-positive lung cancer

Colin Barton, Morhaf Al Achkar, Jennifer A. Blender, Summer Hall Farmen, Raymond B. Hall, Afroditi Maria Konidari, Debbi Martinez, Nancee Pronsati, Marc Rosenzweig, Carla Vass, Emily S. Venanzi, William Westlake, Marc A. T. Muskavitch

PDF Pages: 1303-1319 Full Text (2311) Peer Review File COI Form Open Access

Study Protocol

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)

Taisuke Araki, Shintaro Kanda, Masamichi Komatsu, Kei Sonehara, Kazunari Tateishi, Munetake Takada, Akane Kato, Manabu Yamamoto, Kenichi Nishie, Mineyuki Hama, Toshihiko Agatsuma, Yumiko Kakizaki, Fumiaki Yoshiike, Akemi Matsuo, Tomoshige Chiaki, Kanae Samizo, Yoshiko Takagi, Maki Yamaura, Masayuki Hanaoka, Tomonobu Koizumi

PDF Pages: 1320-1327 Full Text (997) Reporting Checklist Peer Review File COI Form Open Access

Vol 12, No 6 (June 30, 2023): Translational Lung Cancer Research

Editorial

Uniportal versus multiportal VATS segmentectomy: less is more?

Gemcitabine-capecitabine: a therapeutic option in previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Uniportal video-assisted thoracic surgery segmentectomy: a promising new development for thoracic surgery

Follow-up regimen after lung cancer treatment: about the how and why

A national-scale lung cancer research targeting women who underwent surgery

Cancer cachexia research: coming of age

Original Article

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR⁺ non-small-cell lung cancer

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors

Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer

High NHLRC2 expression is associated with shortened survival in lung adenocarcinoma

Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma

A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated EGFR-mutant patients with advanced non-small cell lung cancer

A comparison of the microbiome composition in lower respiratory tract at different sites in early lung cancer patients

Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer

Five-year follow-up after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer: a multicenter study

Review Article

Patient-led advocacy in ALK-positive lung cancer

Study Protocol

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)

Editorial Commentary

Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer

Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer

CLOCK’ing differences in DNA methylation signatures to understand the molecular etiology of lung cancer

Clinical applications of DNA methylation profiling in lung cancer

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer

LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic